{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T02:13:11Z","timestamp":1774059191378,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jgo.2026.102848","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:29:12Z","timestamp":1768829352000},"page":"102848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Graft versus host disease treatment and prevention in older adults: A single-database review"],"prefix":"10.1016","volume":"17","author":[{"given":"William","family":"Ciurylo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahid","family":"Hamparsumian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2026.102848_bb0005","series-title":"Basics of Hematopoietic stem Cell Transplant","article-title":"Indications for allogeneic stem Cell Transplant","author":"Sharma","year":"2023"},{"issue":"17","key":"10.1016\/j.jgo.2026.102848_bb0010","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jgo.2026.102848_bb0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/bmt.2008.253","article-title":"Quality of life and social integration after allogeneic hematopoietic SCT","volume":"42","author":"Bieri","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jgo.2026.102848_bb0020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1046\/j.1365-2141.2000.02053.x","article-title":"Quality of life in 244 recipients of allogeneic bone marrow transplantation","volume":"110","author":"Chiodi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2026.102848_bb0025","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0959-8049(03)00628-2","article-title":"Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 trial","volume":"40","author":"Watson","year":"2004","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.jgo.2026.102848_bb0030","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.bbmt.2020.09.013","article-title":"Barriers to hematopoietic cell transplantation for adults in the united states: a systematic review with a focus on age","volume":"26","author":"Flannelly","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jgo.2026.102848_bb0035","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","article-title":"Comparison of patient age groups in transplantation for myelodysplastic syndrome: the medicare coverage with evidence development study","volume":"6","author":"Atallah","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2026.102848_bb0040","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/hematology.2021000257","article-title":"Allogeneic hematopoietic cell transplantation for older patients","volume":"2021","author":"Lin","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.jgo.2026.102848_bb0045","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbmt.2015.10.019","article-title":"Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jgo.2026.102848_bb0050","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2019.05.037","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the acute Leukemia working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"Ringd\u00e9n","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jgo.2026.102848_bb0055","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1182\/blood-2009-06-225631","article-title":"Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns","volume":"115","author":"Wong","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2026.102848_bb0060","series-title":"Current Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR Summary Slides","author":"Bolon","year":"2022"},{"key":"10.1016\/j.jgo.2026.102848_bb0065","author":"Cancer Stat Facts: Leukemia\u2014Acute Myeloid Leukemia (AML)"},{"issue":"3","key":"10.1016\/j.jgo.2026.102848_bb0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/PPO.0000000000000665","article-title":"Epidemiology and pathogenesis of myelodysplastic syndrome","volume":"29","author":"Rotter","year":"2023","journal-title":"Cancer J"},{"issue":"6","key":"10.1016\/j.jgo.2026.102848_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003138","article-title":"Population ageing and mortality during 1990-2017: a global decomposition analysis","volume":"17","author":"Cheng","year":"2020","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.jgo.2026.102848_bb0080","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1053\/j.seminhematol.2005.09.001","article-title":"Pathophysiology of graft-versus-host disease","volume":"43","author":"Ferrara","year":"2006","journal-title":"Semin Hematol"},{"issue":"9","key":"10.1016\/j.jgo.2026.102848_bb0085","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.bbmt.2014.05.001","article-title":"Impact of age on quality of life, functional status, and survival in patients with chronic Graft-versus-Host Disease","volume":"20","author":"El-Jawahri","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jgo.2026.102848_bb0090","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jtct.2023.03.010","article-title":"Frailty in patients with chronic Graft-versus-Host Disease","volume":"29","author":"Rashid","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jgo.2026.102848_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/bmt.2015.195","article-title":"Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients","volume":"51","author":"Fiuza-Luces","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jgo.2026.102848_bb0100","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3760\/cma.j.issn.0366-6999.20122328","article-title":"Health related quality of life among patients with chronic graft-versus-host disease in China","volume":"126","author":"Mo","year":"2013","journal-title":"Chin Med J"},{"issue":"17","key":"10.1016\/j.jgo.2026.102848_bb0105","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2026.102848_bb0110","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bmt.2009.238","article-title":"Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)","volume":"45","author":"Mitchell","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jgo.2026.102848_bb0115","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.bbmt.2020.05.001","article-title":"Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide","volume":"26","author":"Im","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jgo.2026.102848_bb0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbmt.2015.09.008","article-title":"Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors","volume":"22","author":"Lazaryan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jgo.2026.102848_bb0125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2040620713489842","article-title":"Treatment and management of graft-versus-host disease: improving response and survival","volume":"4","author":"Garnett","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jgo.2026.102848_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/164_2021_544","article-title":"Immune suppression in allogeneic hematopoietic stem cell transplantation","volume":"272","author":"Michniacki","year":"2022","journal-title":"Handb Exp Pharmacol"},{"issue":"8","key":"10.1016\/j.jgo.2026.102848_bb0135","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/bmt.2008.373","article-title":"Prophylaxis regimens for GVHD: systematic review and meta-analysis","volume":"43","author":"Ram","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jgo.2026.102848_bb0140","doi-asserted-by":"crossref","unstructured":"Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009 103(7):975\u201394. doi:https:\/\/doi.org\/10.1016\/j.rmed.2009.01.003. Epub 2009 Apr 15. PMID: 19372037.","DOI":"10.1016\/j.rmed.2009.01.003"},{"issue":"9","key":"10.1016\/j.jgo.2026.102848_bb0145","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jgo.2026.102848_bb0150","article-title":"Immune senescence, immunosenescence and aging","volume":"3","author":"Lee","year":"2022","journal-title":"Front Aging"},{"issue":"3","key":"10.1016\/j.jgo.2026.102848_bb0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31128\/AJGP-10-19-5137","article-title":"Long-term management of elderly patients taking immunosuppressive medications","volume":"49","author":"Ivulich","year":"2020","journal-title":"Aust J Gen Pract"},{"issue":"3","key":"10.1016\/j.jgo.2026.102848_bb0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/bmt.2013.204","volume":"49","author":"Baron","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jgo.2026.102848_bb0165","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/ctr.12405","article-title":"Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan","volume":"28","author":"Iida","year":"2014","journal-title":"Clin Transpl"},{"issue":"4","key":"10.1016\/j.jgo.2026.102848_bb0170","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.bbmt.2014.12.025","article-title":"Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial","volume":"21","author":"Maziarz","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jgo.2026.102848_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jgo.2026.102848_bb0180","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2026.102848_bb0185","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic Graft-versus-Host Disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jgo.2026.102848_bb0190","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no antithymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2026.102848_bb0195","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.jgo.2026.102848_bb0200","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2026.102848_bb0205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","article-title":"Ruxolitinib as salvage therapy for chronic graft versus-host disease","volume":"25","author":"Modi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jgo.2026.102848_bb0210","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8163780","article-title":"Ruxolitinib for therapy of graft-versus-host disease","volume":"2019","author":"Neumann","year":"2019","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.jgo.2026.102848_bb0215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood.2019003125","article-title":"Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial","volume":"135","author":"Pidala","year":"2020","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jgo.2026.102848_bb0220","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jgo.2026.102848_bb0225","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jgo.2026.102848_bb0230","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00277-020-04193-1","article-title":"Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis","volume":"99","author":"Fante","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jgo.2026.102848_bb0235","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.jgo.2026.102848_bb0240","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00277-021-04434-x","article-title":"Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis","volume":"100","author":"Wertheimer","year":"2021","journal-title":"Ann Hematol"},{"issue":"17","key":"10.1016\/j.jgo.2026.102848_bb0245","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with Belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2026.102848_bb0250","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jgo.2026.102848_bb0255","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study [published correction appears in Blood. 2022 mar 17;139(11):1772]","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2026.102848_bb0260","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin InhibitorFree chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2026.102848_bb0265","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(21)00367-7","article-title":"Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial","volume":"9","author":"Zeiser","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jgo.2026.102848_bb0270","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jtct.2021.10.002","volume":"28","author":"Bhatt","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jgo.2026.102848_bb0275","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.phrs.2016.05.015","article-title":"Perspective: targeting the JAK\/STAT pathway to fight age-related dysfunction","volume":"111","author":"Xu","year":"2016","journal-title":"Pharmacol Res"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2026.102848_bb0280","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2021-149612","article-title":"Efficacy and safety of ruxolitinib in the treatment of elderly patients with policythemia vera resistant\/intolerant to hydroxyurea","volume":"138","author":"Latagliata","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jgo.2026.102848_bb0285","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3390\/cells12131722","article-title":"Efficacy and safety of biological therapies and JAK inhibitors in older patients with inflammatory bowel Disease","volume":"12","author":"Fries","year":"2023","journal-title":"Cells"},{"issue":"25","key":"10.1016\/j.jgo.2026.102848_bb0290","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"BMT CTN 1703 investigators. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jgo.2026.102848_bb0295","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/bloodadvances.2025015964","article-title":"Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703","volume":"9","author":"Abedin","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jgo.2026.102848_bb0300","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/s41591-024-03016-4","article-title":"Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial","volume":"30","author":"Chen","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.jgo.2026.102848_bb0305","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"AGAVE-201 investigators. Axatilimab in recurrent or refractory chronic Graft-versus-Host Disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jgo.2026.102848_bb0310","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2018.09.033","article-title":"Patient perspectives regarding allogeneic bone Marrow Transplantation in myelofibrosis","volume":"25","author":"Palmer","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.jgo.2026.102848_bb0315","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2025015793","article-title":"Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704","volume":"9","author":"Sorror","year":"2025","journal-title":"Blood Adv"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:36:51Z","timestamp":1774057011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1879406826000020"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102848","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Graft versus host disease treatment and prevention in older adults: A single-database review","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102848"}}